Abstracts tagged "Allopurinol"

Abstract Number: 0673 • ACR Convergence 2021
The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study
Aniqa Faraz¹, Sabeeh Islam², Joseph Grisanti³ and Shumaila Iqbal⁴, ¹University at Buffalo-CHS Sisters of Charity, Grand Island, NY, ²Brigham and Women's Hospital Cardiology, Boston, MA, ³Buffalo Rheumatology & Medicine, Orchard Park, NY, ⁴University of Cincinnati, Cincinnati, OH
Background/Purpose: The relationship between change in serum uric acid level and progression of chronic kidney disease and hypertension is still conflicting. In this study, we…
Abstract Number: 1900 • ACR Convergence 2021
Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy
James O'Dell¹, Tuhina Neogi², Michael Pillinger³, Paul Palevsky⁴, Jeff Newcomb¹, Mary Brophy⁵, Hongsheng Wu⁵, Annie Davis-Karim⁶, Ryan Ferguson⁵, David Pittman⁶, Robert Terkeltaub⁷, Amy Cannella¹, Bryant England¹, Lindsay Helget¹, Ted Mikuls¹ and Tomas Taylor⁸, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³New York University Grossman School of Medicine, New York,, NY, ⁴Pittsburgh University, Pittsburgh, PA, ⁵Boston VA, Boston, MA, ⁶Albuquerque VA, Albuquerque, NM, ⁷VA/UCSD, San Diego, CA, ⁸White River Junction VA, White River Junction, VT
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety…
Abstract Number: 339 • 2019 ACR/ARP Annual Meeting
Depressive Symptoms Influence Success of Allopurinol in Reducing Serum Urate
Sylvie Mrug ¹, Catheryn Orihuela ¹, Elizabeth Rahn ², Amy Mudano ¹, Kenneth Saag ², Jeffrey Foster ² and Angelo Gaffo², ¹University of Alabama at Birmingham, Birmingham, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Elevated levels of serum urate (sUA) are central to the pathogenesis of gout and have been associated with cardiovascular disease. Urate-lowering therapies are effective…
Abstract Number: 900 • 2019 ACR/ARP Annual Meeting
Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults
Angelo Gaffo¹, David Calhoun ², Elizabeth Rahn ¹, Suzanne Oparil ², Peng Li ², Tanja Dudenbostel ², David Redden ², Amy Mudano ², Jeffrey Foster ¹, Daniel Feig ², Stephanie Biggers ² and Kenneth Saag ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham
Background/Purpose: An effect of serum urate on vascular endothelium has been postulated as a mechanism for its association with hypertension and cardiovascular disease. Prior studies…
Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Neus Quilis¹, Laura Ranieri², Jose Sanchez-Paya² and Mariano Andrés², ¹Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…
Abstract Number: 1272 • 2018 ACR/ARHP Annual Meeting
Quality of Gout Management in a Rheumatology Clinic Using a Provider-Pharmacist Team-Based Approach
Jessica Michaud¹ and Jenna Beatty², ¹Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, ²University of Kansas, kansas city, MO
Background/Purpose: Gout is the most common form of inflammatory arthritis.1 The cornerstone of treatment for gout is urate-lowering therapy (ULT), which in the U.S. includes…
Abstract Number: 1292 • 2018 ACR/ARHP Annual Meeting
HLA-B*58:01 Genotype and the Risk of Allopurinol-Associated Severe Cutaneous Adverse Reactions in a Predominately Black or African American Population with Advanced Chronic Kidney Disease
Sarah Ford¹, Pamela Kimball¹, Gaurav Gupta¹ and Nehal Shah², ¹Virginia Commonwealth University, Richmond, VA, ²Medicine/Rheumatology, Virginia Commonwealth University, Richmond, VA
Background/Purpose: Allopurinol is the first line urate lowering drug used for treatment of gout. Its most feared side effect includes development of hypersensitivity drug reactions…
Abstract Number: 2220 • 2018 ACR/ARHP Annual Meeting
Gout, Flares and Allopurinol Use: A Population Based Study
Charlotte Proudman¹, Susan Lester^2,3, David Gonzalez-Chica⁴, Tiffany Gill³, Nicola Dalbeth⁵ and Catherine Hill^6,7, ¹Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ²Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, ³Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ⁴Discipline of General Practice, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ⁵Department of Medicine, Faculty of Medical and Health Sciences., University of Auckland, Auckland, New Zealand, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷Medicine, The University of Adelaide, Adelaide, Australia
Background/Purpose: Gout flares may often be self-managed, but there is a paucity of population-based data. The aim of this study was to determine the prevalence…
Abstract Number: 2237 • 2018 ACR/ARHP Annual Meeting
Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
Michael Chen-Xu¹, Chio Yokose², Michael Pillinger³ and Hyon K. Choi², ¹General Medicine, Wairarapa District Health Board, Masterton, New Zealand, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: To determine the latest national prevalence of urate-lowering therapy (ULT) use and achievement of a therapeutic target serum urate level (SUL) in gout patients,…
Abstract Number: 2242 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
William B. White¹ and Lhanoo Gunawardhana², ¹Cardiology, University of Connecticut School of Medicine, Farmington, CT, ²Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES) trial demonstrated that major cardiovascular (CV) outcomes on febuxostat…
Abstract Number: 2253 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease, Other Purported Risk Factors, and Allopurinol-Associated Severe Cutaneous Adverse Reactions: A General Population-Based Cohort Study
Na Lu¹, Chio Yokose², Hui Xie^1,3, Gloria Li¹, Sharan K. Rai^4,5, Seoyoung C. Kim⁶ and Hyon K. Choi², ¹Arthritis Research Canada, Richmond, BC, Canada, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁵Graduate School of Arts and Sciences, Harvard University, Cambridge, MA, ⁶Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A recent US Medicaid study found that in addition to certain races (Asians and Blacks), older age, female sex, chronic kidney disease (CKD), and…
Abstract Number: 873 • 2018 ACR/ARHP Annual Meeting
General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
Kenneth Saag¹, Michael A. Becker², William B. White³, Andrew Whelton⁴, Jeffrey Borer⁵, Philip Gorelick⁶, Barbara Hunt⁷, Majin Castillo⁷ and Lhanoo Gunawardhana⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago Pritzker School of Medicine, Chicago, IL, ³Cardiology, University of Connecticut School of Medicine, Farmington, CT, ⁴Johns Hopkins University School of Medicine, Hunt Valley, MD, ⁵State University of New York Downstate Medical Center, Brooklyn, NY, ⁶Michigan State University College of Human Medicine, Grand Rapids, MI, ⁷Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The cardiovascular (CV) safety study CARES has the longest study duration of any randomized controlled trial in patients (pts) with gout and CV disease.…
Abstract Number: 1128 • 2018 ACR/ARHP Annual Meeting
Impact of Urate-Lowering Therapy on the Risk of Cardiovascular Events and All-Cause Mortality Among Individuals with Gout
In Ah Choi¹, Hoyeon Jang² and Gil-Won Kang², ¹Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, Republic of (South), ²Department of Health Informatics and Management, College of Medicine, Chungbuk National University, Cheongju, Korea, Republic of (South)
Background/Purpose: Gout results from an increased body pool of urate that occurs with hyperuricemia. Although urate-lowering therapy (ULT) is beneficial to prevent gout attack, current…
Abstract Number: 1247 • 2018 ACR/ARHP Annual Meeting
Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management
Irvin Huang¹, Jean Liew², Meredith Barnes³, Silu Zuo⁴, Carol Crawford⁴ and Alison Bays⁵, ¹Internal Medicine, Boise VAMC, Boise, ID, ²Internal Medicine; Division of Rheumatology, University of Washington, Seattle, WA, ³Medicine, University of Washington, Seattle, WA, ⁴Harborview Medical Center, Seattle, WA, ⁵Division of Rheumatology, University of Washington, Seattle, CA
Background/Purpose: The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines.…
Abstract Number: 1265 • 2018 ACR/ARHP Annual Meeting
The Challenges of Managing Gout in Primary Care: Results of a Best Practice Audit
Lisa K. Stamp¹, Peter T. Chapman², Ben Hudson³, Greg Hamilton⁴ and Andrea Judd⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴Canterbury District Health Board, Christchurch, New Zealand, ⁵Kaikoura Medical Centre, Kaikoura, New Zealand
Background/Purpose: The majority of gout management occurs in primary care and may be suboptimal. While community based clinical trials have reported improvements whether such improvements…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].